| Species |
Cynomolgus |
| Protein Construction |
PLAU/uPA (Ser21-Leu430)
Accession # A0A2K5WND1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized PLAU/uPA (active form), His, Cynomolgus at 2μg/ml (100μl/well) on the plate can bind Human uPAR, hFc Tag. Test result was comparable to standard batch. Measured by its ability to cleave a peptide substrate,NcarbobenzyloxyGlyGlyArg7amido4methylcoumarin (ZGGRAMC). The specific activity is >2000 pmol/min/μg. Test result meets the standard. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
47.23 kDa |
| Apparent Molecular Weight |
Due to protein lysis and glycosylation, the protein migrates to 23-25 kDa (long chain A), 35-40 kDa (chain B) and 50-60 kDa (long chain A&chain B) based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Plasminogen activator, urokinase (uPA) is a secreted serine protease whose Dysregulation is often accompanied by various cancers. PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC. |
| Synonyms |
PLAU; Urokinase; ATF; UPA; URK; u-PA; BDPLT5; QPD |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
